Kodiak Sciences Inc. (FRA:K27)

Germany flag Germany · Delayed Price · Currency is EUR
20.76
-0.58 (-2.72%)
At close: Jan 30, 2026
213.12%
Market Cap1.19B +157.8%
Revenue (ttm)n/a
Net Income-185.24M
EPS-3.51
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume128
Open20.76
Previous Close21.34
Day's Range20.76 - 20.76
52-Week Range1.72 - 27.60
Betan/a
RSI45.70
Earnings DateMar 26, 2026

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 123
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol K27
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements